Double maintains 4 strategies that include RARE - Ultragenyx Pharmaceutical, Inc.
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| CANE | 0.14% | $11.14M | 0.29% |
| BILS | 0.73% | $3.80B | 0.1356% |
| TBLL | 0.83% | $2.12B | 0.08% |
| FXY | 0.84% | $802.69M | 0.4% |
| FTSD | -0.90% | $233.11M | 0.25% |
| LDUR | 0.92% | $922.12M | 0.5% |
| AGGH | 1.21% | $321.29M | 0.29% |
| STOT | -1.31% | $252.82M | 0.45% |
| UNG | 1.38% | $375.27M | 1.06% |
| BIL | -1.43% | $41.93B | 0.1356% |
| XHLF | -1.55% | $1.73B | 0.03% |
| WEAT | 1.75% | $123.28M | 0.28% |
| STPZ | 1.80% | $443.27M | 0.2% |
| BUXX | 2.11% | $312.40M | 0.25% |
| KRBN | 2.65% | $159.82M | 0.85% |
| TDTT | 2.93% | $2.63B | 0.18% |
| AGZD | 2.96% | $98.56M | 0.23% |
| PSQA | -3.07% | $36.49M | 0.2% |
| KMLM | 3.33% | $187.82M | 0.9% |
| SMB | 3.38% | $276.62M | 0.07% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 55.72% | $4.81B | 0.35% |
| GNOM | 55.31% | $46.47M | 0.5% |
| IBB | 50.71% | $5.37B | 0.45% |
| PTH | 46.78% | $96.25M | 0.6% |
| ARKG | 45.71% | $1.03B | 0.75% |
| PBE | 45.57% | $226.91M | 0.58% |
| PINK | 45.31% | $130.30M | 0.5% |
| BBH | 45.14% | $339.54M | 0.35% |
| FBT | 44.84% | $1.02B | 0.54% |
| XPH | 43.61% | $150.58M | 0.35% |
| VHT | 40.02% | $15.34B | 0.09% |
| IHAK | 39.99% | $958.15M | 0.47% |
| AOM | 39.89% | $1.52B | 0.15% |
| FHLC | 39.74% | $2.43B | 0.084% |
| BUG | 39.31% | $1.20B | 0.51% |
| QDVO | 39.04% | $90.31M | 0.55% |
| HACK | 38.97% | $2.37B | 0.6% |
| IWO | 38.70% | $11.77B | 0.24% |
| AOR | 38.63% | $2.52B | 0.15% |
| CIBR | 38.49% | $10.17B | 0.59% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NRIX | 46.94% | $965.91M | -42.49% | 0.00% |
| CRNX | 46.75% | $3.00B | -39.42% | 0.00% |
| RVMD | 45.95% | $7.17B | -11.19% | 0.00% |
| IONS | 43.82% | $6.75B | -10.42% | 0.00% |
| DNLI | 42.96% | $2.23B | -33.52% | 0.00% |
| DASH | 42.80% | $100.95B | +125.99% | 0.00% |
| IDYA | 42.71% | $2.00B | -42.45% | 0.00% |
| RGNX | 42.09% | $456.52M | -28.72% | 0.00% |
| XNCR | 42.04% | $660.47M | -52.14% | 0.00% |
| RNA | 41.56% | $3.79B | -28.98% | 0.00% |
| ARWR | 41.50% | $2.60B | -33.24% | 0.00% |
| DYN | 41.18% | $1.25B | -79.03% | 0.00% |
| KYMR | 40.62% | $3.17B | +15.92% | 0.00% |
| NUVL | 40.60% | $5.89B | +5.23% | 0.00% |
| ARCT | 40.33% | $392.71M | -39.06% | 0.00% |
| ZYME | 40.09% | $959.66M | +38.40% | 0.00% |
| BEAM | 39.87% | $2.22B | -14.88% | 0.00% |
| XENE | 39.40% | $2.53B | -19.91% | 0.00% |
| OCUL | 38.62% | $1.77B | +45.79% | 0.00% |
| SEVN | 38.59% | $167.91M | -14.92% | 12.48% |
Yahoo
Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are resolvable FDA clinical reviews acknowledged that the clinical data are robust and biomarker data are supportive NOVATO, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its Biologics License Application (BLA) for UX111 (ABO-10
Finnhub
By Dean Seal Ultragenyx Pharmaceutical said federal regulators have issued a complete response letter to its application for a metabolic disorder treatment that may delay the potential approval to...
Finnhub
The U.S. Food and DrugAdministration has declined to approve UltragenyxPharmaceutical's experimental gene therapy to treat arare inherited disorder, citing manufacturing concerns, thecompany said...
Finnhub
The U.S. Food and DrugAdministration has declined to approve UltragenyxPharmaceutical's experimental gene therapy to treat arare genetic disorder, the company said on Friday.(Reporting by Kamal...
Yahoo
Current operations chief Renee Gala will succeed Bruce Cozadd at Jazz. Meanwhile, a key study of an Ultragenyx and Mereo drug is continuing past a second interim analysis.
Yahoo
Health care stocks advanced late Thursday afternoon, with the NYSE Health Care Index rising 0.9% and
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| QTTB | -24.44% | $40.50M | -85.20% | 0.00% |
| KLG | -21.47% | $1.97B | +42.70% | 2.84% |
| MP | -19.84% | $7.39B | +203.97% | 0.00% |
| VHC | -10.08% | $69.05M | +176.10% | 0.00% |
| LITB | -8.88% | $24.26M | -71.62% | 0.00% |
| CNC | -8.64% | $16.18B | -51.64% | 0.00% |
| AIFU | -7.28% | $17.40M | +87.81% | 0.00% |
| HUSA | -6.74% | $20.99M | -8.33% | 0.00% |
| BTCT | -6.55% | $28.19M | +79.43% | 0.00% |
| KR | -6.37% | $46.75B | +34.05% | 1.81% |
| MO | -5.26% | $98.62B | +24.36% | 7.00% |
| CARV | -4.96% | $9.39M | +24.99% | 0.00% |
| ED | -4.91% | $36.42B | +10.51% | 3.36% |
| TDUP | -4.87% | $807.63M | +285.88% | 0.00% |
| AQB | -4.38% | $3.04M | -56.34% | 0.00% |
| CCEC | -4.34% | $1.02B | +3.91% | 2.48% |
| FARO | -4.29% | $848.21M | +159.82% | 0.00% |
| AWK | -4.16% | $27.82B | +4.74% | 2.18% |
| CVM | -4.12% | $20.33M | -89.73% | 0.00% |
| CNX | -3.88% | $4.82B | +28.19% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TAIL | -24.79% | $94.86M | 0.59% |
| BTAL | -24.11% | $315.93M | 1.43% |
| VIXY | -22.83% | $184.73M | 0.85% |
| TPMN | -13.39% | $31.06M | 0.65% |
| USDU | -10.56% | $129.80M | 0.5% |
| UUP | -10.14% | $196.45M | 0.77% |
| IVOL | -7.78% | $342.69M | 1.02% |
| SHYM | -6.25% | $355.86M | 0.35% |
| JMST | -5.84% | $4.09B | 0.18% |
| TFLO | -5.83% | $6.74B | 0.15% |
| KCCA | -5.82% | $108.37M | 0.87% |
| ULST | -5.75% | $592.38M | 0.2% |
| BILZ | -5.38% | $851.85M | 0.14% |
| CTA | -4.87% | $1.08B | 0.76% |
| USFR | -4.54% | $18.61B | 0.15% |
| CLIP | -3.80% | $1.55B | 0.07% |
| PSQA | -3.07% | $36.49M | 0.2% |
| XHLF | -1.55% | $1.73B | 0.03% |
| BIL | -1.43% | $41.93B | 0.1356% |
| STOT | -1.31% | $252.82M | 0.45% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| FIZZ | 0.01% | $4.21B | -10.24% | 0.00% |
| ZTO | 0.03% | $11.48B | -4.50% | 3.72% |
| LTM | -0.07% | $12.85B | -95.43% | 2.39% |
| AEP | -0.11% | $56.65B | +16.73% | 3.49% |
| HRB | -0.13% | $7.60B | +6.69% | 2.63% |
| VRCA | 0.13% | $80.70M | -89.71% | 0.00% |
| FYBR | -0.20% | $9.18B | +37.14% | 0.00% |
| UTZ | 0.26% | $1.19B | -10.16% | 1.76% |
| PINC | -0.28% | $1.77B | +13.85% | 3.92% |
| TNK | 0.31% | $1.53B | -29.16% | 2.27% |
| PPC | -0.34% | $10.64B | +33.60% | 0.00% |
| HSY | -0.44% | $33.36B | -11.86% | 3.35% |
| HOLX | 0.44% | $14.90B | -12.60% | 0.00% |
| DUK | 0.49% | $91.85B | +13.12% | 3.57% |
| TPB | -0.49% | $1.30B | +101.13% | 0.40% |
| EDU | 0.52% | $8.65B | -29.86% | 0.00% |
| WTRG | -0.53% | $10.52B | -6.15% | 3.49% |
| OCFT | -0.55% | $274.85M | +317.32% | 0.00% |
| CBOE | -0.64% | $24.55B | +38.09% | 1.08% |
| VSTA | -0.68% | $325.62M | +30.97% | 0.00% |
Current Value
$30.641 Year Return
Current Value
$30.641 Year Return
